83 related articles for article (PubMed ID: 12716291)
1. Preclinical Changes in Immunoreactivity and Cellular Architecture during the Progressive Development of Intracranial Neoplasms and an Immunotherapeutic Schedule with a Novel Biological Response Modifier, the T11TS / S-LFA3.
Mukherjee J; Dutta S; Sarkar S; Begum Z; Ghosh A; Chaudhuri S; Chaudhuri S
Asian Pac J Cancer Prev; 2002; 3(4):325-337. PubMed ID: 12716291
[TBL] [Abstract][Full Text] [Related]
2. Immunotherapeutic effects of T11TS/S-LFA3 against nitrosocompound mediated neural genotoxicity.
Mukherjee J; Sarkar S; Ghosh A; Duttagupta AK; Chaudhuri S; Chaudhuri S
Toxicol Lett; 2004 May; 150(3):239-57. PubMed ID: 15110076
[TBL] [Abstract][Full Text] [Related]
3. CD2-SLFA3/T11TS interaction facilitates immune activation and glioma regression by apoptosis.
Sarkar S; Ghosh A; Mukherjee J; Chaudhuri S; Chaudhuri S
Cancer Biol Ther; 2004 Nov; 3(11):1121-8. PubMed ID: 15467439
[TBL] [Abstract][Full Text] [Related]
4. Comparative evaluation of T11 target structure and its deglycosylated derivative nullifies the importance of glycan moieties in immunotherapeutic efficacy.
Chatterjee S; Acharya S; Kumar P; Chatterjee A; Chaudhuri S; Ghosh A; Chaudhuri S
Acta Biochim Biophys Sin (Shanghai); 2012 Mar; 44(3):259-68. PubMed ID: 22257732
[TBL] [Abstract][Full Text] [Related]
5. Immunotherapy with T11TS / S-LFA-3 specifically induces apoptosis of brain tumor cells by augmenting intracranial immune status.
Mukherjee J; Ghosh A; Sarkar P; Mazumdar M; Banerjee C; Chaudhuri S
Anticancer Res; 2005; 25(4):2905-19. PubMed ID: 16080544
[TBL] [Abstract][Full Text] [Related]
6. Sheep form of leucocyte function antigen-3 (T11TS) exerts immunostimulatory and anti-tumor activity against experimental brain tumor. A new approach to biological response modifier therapy.
Sarkar S; Begum Z; Dutta S; Dutta SK; Chaudhuri S; Chaudhuri S
J Exp Clin Cancer Res; 2002 Mar; 21(1):95-106. PubMed ID: 12071536
[TBL] [Abstract][Full Text] [Related]
7. ENU administration causes genomic instability along with single nucleotide polymorphisms in p53 during gliomagenesis: T11TS administration demonstrated in vivo apoptosis of these genetically altered tumor cells.
Mukherjee J; Ghosh A; Ghosh A; Chaudhuri S
Cancer Biol Ther; 2006 Feb; 5(2):156-64. PubMed ID: 16357521
[TBL] [Abstract][Full Text] [Related]
8. Documentation of immune profile of microglia through cell surface marker study in glioma model primed by a novel cell surface glycopeptide T11TS/SLFA-3.
Begum Z; Ghosh A; Sarkar S; Mukherjee J; Mazumdar M; Sarkar P; Chaudhuri S
Glycoconj J; 2004; 20(9):515-23. PubMed ID: 15454689
[TBL] [Abstract][Full Text] [Related]
9. T11TS/S-LFA3 induces apoptosis of the brain tumor cells: a new approach to characterise the apoptosis associated genetic changes by arbitrarily primed-PCR.
Mukherjee J; Ghosh A; Sarkar S; Mazumdar M; Sarkar P; Duttagupta AK; Chaudhuri S
Cancer Lett; 2005 May; 222(1):23-38. PubMed ID: 15837538
[TBL] [Abstract][Full Text] [Related]
10. The novel immunotherapeutic molecule T11TS modulates glioma-induced changes of key components of the immunological synapse in favor of T cell activation and glioma abrogation.
Chaudhuri S; Singh MK; Bhattacharya D; Acharya S; Chatterjee S; Kumar P; Bhattacharjee P; Basu AK; Sa G; Das T; Ghosh TK; Chaudhuri S
J Neurooncol; 2014 Oct; 120(1):19-31. PubMed ID: 25026997
[TBL] [Abstract][Full Text] [Related]
11. Brain tumor inhibition in experimental model by restorative immunotherapy with a corpuscular antigen.
Gangopaddhyay SK; Sarkar S; Begum Z; Chaudhuri S; Chaudhuri S
Indian J Exp Biol; 2003 Aug; 41(8):805-13. PubMed ID: 15248476
[TBL] [Abstract][Full Text] [Related]
12. Bax and Bid act in synergy to bring about T11TS-mediated glioma apoptosis via the release of mitochondrial cytochrome c and subsequent caspase activation.
Bhattacharjee M; Acharya S; Ghosh A; Sarkar P; Chatterjee S; Kumar P; Chaudhuri S
Int Immunol; 2008 Dec; 20(12):1489-505. PubMed ID: 18931364
[TBL] [Abstract][Full Text] [Related]
13. T11 target structure exerts effector function by activating immune cells in CNS against glioma where cytokine modulation provide favorable microenvironment.
Ghosh A; Bhattacharya M; Sarkar P; Acharya S; Chaudhuri S
Indian J Exp Biol; 2010 Sep; 48(9):879-88. PubMed ID: 21506495
[TBL] [Abstract][Full Text] [Related]
14. Rosetting of human T lymphocytes with sheep and human erythrocytes. Comparison of human and sheep ligand binding using purified E receptor.
Selvaraj P; Dustin ML; Mitnacht R; Hünig T; Springer TA; Plunkett ML
J Immunol; 1987 Oct; 139(8):2690-5. PubMed ID: 3309056
[TBL] [Abstract][Full Text] [Related]
15. T11TS inhibits Angiopoietin-1/Tie-2 signaling, EGFR activation and Raf/MEK/ERK pathway in brain endothelial cells restraining angiogenesis in glioma model.
Bhattacharya D; Chaudhuri S; Singh MK; Chaudhuri S
Exp Mol Pathol; 2015 Jun; 98(3):455-66. PubMed ID: 25797371
[TBL] [Abstract][Full Text] [Related]
16. T11TS, the cell surface molecule binding to the "erythrocyte receptor" of T lymphocytes: cellular distribution, purification to homogeneity and biochemical properties.
Hünig T; Mitnacht R; Tiefenthaler G; Köhler C; Miyasaka M
Eur J Immunol; 1986 Dec; 16(12):1615-21. PubMed ID: 2880724
[TBL] [Abstract][Full Text] [Related]
17. Regulation of key molecules of immunological synapse by T11TS immunotherapy abrogates Cryptococcus neoformans infection in rats.
Sk Md OF; Hazra I; Datta A; Mondal S; Moitra S; Chaudhuri S; Das PK; Basu AK; Mishra R; Chaudhuri S
Mol Immunol; 2020 May; 122():207-221. PubMed ID: 32388483
[TBL] [Abstract][Full Text] [Related]
18. A comparative analysis of immunorestoration and recovery with conventional and immunotherapeutic protocols in canine generalized demodicosis: a newer insight of immunotherapeutic efficacy of T11TS.
Sarkar P; Mukherjee J; Ghosh A; Bhattacharjee M; Mahato S; Chakraborty A; Mondal M; Banerjee C; Chaudhuri S
Immunol Invest; 2004; 33(4):453-68. PubMed ID: 15624702
[TBL] [Abstract][Full Text] [Related]
19. The "erythrocyte receptor" of T-lymphocytes and T11 target structure (T11TS): complementary cell interaction molecules involved in T-cell activation.
Hünig T; Tiefenthaler G; Mitnacht R; Köhler C; Lottspeich F; Meuer S
Behring Inst Mitt; 1987 Jun; (81):31-40. PubMed ID: 2888455
[TBL] [Abstract][Full Text] [Related]
20. Purified lymphocyte function-associated antigen-3 and T11 target structure are active in CD2-mediated T cell stimulation.
Tiefenthaler G; Hünig T; Dustin ML; Springer TA; Meuer SC
Eur J Immunol; 1987 Dec; 17(12):1847-50. PubMed ID: 2891540
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
